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funBACKGROUND The mechanisms underlying early atherosclerotic plaque formation are not completely understood.
Moreover, plasma biomarkers of subclinical atherosclerosis are lacking.
OBJECTIVES The purpose of this study was to analyze the temporal and topologically resolved protein changes taking
place in human aortas with early atherosclerosis to find new potential diagnostic and/or therapeutic targets.
METHODS The protein composition of healthy aortas (media layer) or with early atheroma (fatty streak and fibrolipidic,
media and intima layers) was analyzed by deep quantitative multiplexed proteomics. Further analysis was performed by
Western blot, immunohistochemistry, real-time polymerase chain reaction, and enzyme-linked immunosorbent assay.
Plasma levels of complement C5 were analyzed in relation to the presence of generalized (>2 plaques) or incipient (0 to 2
plaques) subclinical atherosclerosis in 2 independent clinical cohorts (PESA [Progression of Early Subclinical Athero-
sclerosis] [n ¼ 360] and NEFRONA [National Observatory of Atherosclerosis in Nephrology] [n ¼ 394]).
RESULTS Proteins involved in lipid transport, complement system, immunoglobulin superfamily, and hemostasis are
increased in early plaques. Components from the complement activation pathway were predominantly increased in the
intima of fibrolipidic plaques. Among them, increased C5 protein levels were further confirmed by Western blot, enzyme-
linked immunosorbent assay and immunohistochemistry, and associated with in situ complement activation. Plasma C5
was significantly increased in individuals with generalized subclinical atherosclerosis in both PESA and NEFRONA cohorts,
independently of risk factors. Moreover, in the PESA study, C5 plasma levels positively correlated with global plaque
volume and coronary calcification.
CONCLUSIONS Activation of the complement system is a major alteration in early atherosclerotic plaques and is
reflected by increased C5 plasma levels, which have promising value as a novel circulating biomarker of
subclinical atherosclerosis. (J Am Coll Cardiol 2020;75:1926–41) © 2020 The Authors. Published by Elsevier on behalf
of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2020.02.058
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AB BR EV I A T I O N S
AND ACRONYM S
C5 = complement C5
C9 = complement component
C9
CACS = coronary artery
calcium score
CD59 = CD59 glycoprotein
FL = fibrolipidic
FS = fatty streak(s)
VUS = vascular ultrasound
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1927A therosclerosis is a complex disease that de-velops over decades, but is usually detectedonly at advanced symptomatic stages or after
a cardiovascular (CV) event. Recent data reveal that
subclinical atherosclerosis is highly prevalent in
middle-aged, asymptomatic individuals (1). Detection
of subclinical atherosclerosis improves risk stratifica-
tion (2), highlighting the need for new tools (e.g., im-
aging or molecular biomarkers) to identify
asymptomatic patients at risk. Moreover, current
treatments targeting conventional risk factors are of
limited value, because atherosclerosis and CV events
are known to occur in individuals without risk factors
(3). This suggests that beyond risk factors, atherogen-
esis involves mechanisms and mediators, which
could be important in the initial stages of the wall pa-
thology before its clinical expression. The accepted
paradigm is that atherosclerosis initiation takes
place by a 2-step process. First, the translation of
circulating lipids to the vascular wall and their
retention in the subendothelium (4), forming fatty
streaks (FS). This lipid retention then triggers a pro-
cess of smooth muscle cell migration and prolifera-
tion to form the neointimal fibrocellular cap, which
encapsulates the lipid core to form a fibrolipidic
(FL) plaque (5). A more comprehensive analysis of
the molecular mechanisms underlying this initial
pathophysiology in human atherosclerosis could
help to identify new diagnostic and/or therapeutic
targets.SEE PAGE 1942Different proteomics approaches have been used to
identify new biomarkers or therapeutic targets in
humans (6). At early disease stages, Van Eycks group
recently analyzed whole plaques from coronary and
aortic arterial territories detecting an increase in
mitochondrial proteins in coronary atherosclerotic
plaques; that study also revealed a subset of tissue
protein biomarkers found in plasma indicative of early
disease in a small cohort (7). Proteomics has also been
used to analyze extracellular matrix components of
advanced atherosclerotic plaques, identifying a panel
of 4 biomarkers that predict CV risk in 2 large patient
cohorts (8). These studies reveal that tissue-
proteomics may be a promising approach in the
search for biomarkers able to predict atherosclerosis.de hacer Europa.” The CNIC is supported by the Instituto de Salud Carlos
Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa
have reported that they have no relationships relevant to the contents of th
Guest Associate Editor for this paper.
Manuscript received December 23, 2019; revised manuscript received JanuaGiven the multiplicity of cell types and
molecules involved in atherosclerosis and
their variation between compartments and
stages, we designed a proteomics analysis of
specific regions (media and intima) in 2
consecutive stages of early atherosclerotic
lesions (FS and FL plaques). The protein
composition of each of these compartments
and the pattern of protein alterations that
take place along early plaque development
have never been analyzed before from a
proteome-wide approach. Moreover, due to
the systemic nature of the disease, this proteomics
analysis of vascular tissue has the potential to iden-
tify circulating biomarkers that could be useful in the
diagnosis of patients with asymptomatic
atherosclerosis.
METHODS
A detailed description of the methods can be found in
the Supplemental Appendix.
HUMAN TISSUE SAMPLES. Abdominal aortic samples
(healthy [H], FS, or FL plaques [Supplemental
Figure 1]) were obtained from brain-deceased organ
donors (artificially ventilated, with a beating heart or
cold-perfused body) during organ removal for thera-
peutic transplantation (kidney or liver trans-
plantation) with the authorization of the French
Biomedicine Agency (PFS 09-007, BRIF BB-0033-
00029; AoS BBMRI-EU/infrastructure BIOBANQUE;
No. Access: 2, last: April 15, 2014. [BIORESOURCE]).
The aortic tissue was washed and preserved in ringer
lactate at 4C until use. The whole aortic sample was
macroscopically processed and dissected, with
removal of the adventitia, followed by separation of
the intima and media only in FS and FL plaques (as in
the healthy aorta, the intima was too thin to be
separated from the media).
Aortic samples (100 mg) from media (H [n ¼ 9], FSm
[n ¼ 7], and FLm [n ¼ 11]) and intima (FSi [n ¼ 6] and
FLi [n ¼ 12]) were homogenized within liquid N2 and
protein/mRNA lysates were extracted, quantified,
and kept at 80o C until further analysis.
Specific tissue-conditioned medium was obtained
by cutting tissue samples (intima and media sepa-
rately) into small pieces (5 mm2) and incubated themIII (ISCIII), the Ministerio de Ciencia, Innovación y
Center of Excellence (SEV-2015-0505). The authors
is paper to disclose. Jay W. Heinecke, MD, served as
ry 25, 2020, accepted February 18, 2020.
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1929in RPMI 1640 medium without FBS for 24 h at 37C
(6 ml/g of wet tissue). The tissue-conditioned me-
dium was collected after centrifugation and frozen
at 80o C.
PROTEOMICS. Briefly, protein extracts were trypsin-
digested and the resulting peptides were labeled
with 10-plex TMT isobaric labelling and fractionated.
Fractions were subjected to LC-MS/MS analysis using
an Orbitrap Fusion mass spectrometer (Thermo
Fisher Scientific, Waltham, Massachusetts). Identifi-
cation, quantification, and systems-biology analysis
were performed as described (9–13).
WESTERN BLOT. Equal protein amounts (10 ug) from
homogenized tissues were resolved in sodium
dodecyl sulfate–polyacrylamide gel electrophoresis.
Membranes were incubated with antibodies against
C5 (A396, Quidel, San Diego, California) and glycer-
aldehyde 3-phosphate dehydrogenase (GADPH)
(MAB374, Millipore, Billerica, Massachusetts) and
processed as described (14).
IMMUNOHISTOCHEMISTRY. Paraffin aortic samples
were incubated with primary antibodies against C5
(A306, Quidel) or an anti C9 (a generous gift of Prof. P.
Morgan, Cardiff University, United Kingdom) as
described (14).
REAL-TIME POLYMERASE CHAIN REACTION. Human
pathological and control tissues were snap frozen in
liquid N2 and homogenates (0.2 g) were divided
and resuspended for mRNA analysis of C5
(Hs01004342_m1), CD59 (Hs00174141_m1), comple-
ment decay-accelerating factor (Hs00892618_m1), and
GADPH (Hs02786624_g1) as described (14).
ENZYME-LINKED IMMUNOSORBENT ASSAY. Plates
(Costar #33669) were coated with capture antihuman
C5 antibody eculizumab overnight. A calibration
curve was constructed with known concentrations of
purified C5 (Complement Technology, Tyler, Texas).
Detecting goat antihuman C5 (Quidel, A306) and HRP
conjugated rabbit anti-goat (Cat P0160, DAKO, Troy,
Michigan) were used. The enzyme-linked immuno-
sorbent assay (ELISA) was developed with OPDFIGURE 1 Continued
(A) Heat map showing protein abundance changes (Zq) in the media lay
value in healthy aorta (H). Increased (red) or decreased (blue) abundanc
the statistically significant abundance changes. (B) Correlation between
differentially expressed in the media layer of atherosclerotic tissue. The b
the main biological processes (GOBP categories) that are significantly enr
obtained for Bonferroni enrichment. Only the significantly enriched GOBP
represents the logarithm of Bonferroni-corrected p values of category e
Table 2.substrate (Cat. P9187, Sigma, St. Louis, Missouri).
Intraprecision and interprecision coefficients of vari-
ation were 6.7% and 9%, respectively.
For sC5b-9, we used the following reagents:
coating antibody (Goat a-Mouse IgG2a, Human ads-
UNLB, Cat #1080-01 Southern Biotech, Birmingham,
Alabama); first antibody (Anti-Human TCC, Cat
#HM2167, Hycult Biotech, Wayne Pennsylvania),
detecting antibody (1:1 mix of the antiC5 mouse
monoclonals SIM378.11.2.1 and SIM378.55.1.1); and
goat antimouse IgG1 (human ads-HRP Southern
Biotech, Cat #1070-05).
C5a and CD59 were detected with commercial
ELISAs (DY2037, R&D, Minneapolis, Minnesota; and
RAB1027, Sigma, respectively) following man-
ufacturers instructions. Samples with a code were
randomly distributed between plates, and the
personnel who performed the ELISA were blinded to
the clinical data associated to the codes of samples.
HUMAN PLASMA SAMPLES. Test cohort . The study
population consisted of 360 male participants
enrolled in the PESA study (1). The PESA study is
aimed at detecting early atherosclerosis in a middle
age (age 40 to 54 years) low-risk population by
noninvasive imaging, including 2-dimensional (2D)
and 3-dimensional (3D) vascular ultrasound (VUS) for
peripheral atherosclerosis evaluation and non-
contrast cardiac computed tomography (CT) for cor-
onary artery calcium score (CACS) quantification. All
participants were free of clinically apparent CV dis-
ease and had a normal renal function. The institu-
tional ethics committee approved the study
protocol, and all participants provided written
informed consent.
Val idat ion cohort . The study population consisted
of 394 control participants (54% men, 46% women)
from the NEFRONA study (15). Participants were
enrolled at 9 Spanish primary care centers distributed
across 7 Spanish regions. They were free of overt CV
disease, active infections, or kidney impairment, and
were examined for the presence of subclinical
atherosclerosis with 2DVUS. Each local ethicser of fatty streak (FSm) and fibrolipidic (FLm) plaques in relation to the average
es are expressed according to the indicated Zq scale. The inset at the right show
identified proteins from FS and FL media. (C) Enrichment analysis of proteins
ars show the relative proportion of changing proteins that belong to each one of
iched. Bars are color-coded according to log2(p), where p refers to the p value
s are shown [log2(p) ¼ 5 correspond to a p value <0.05]. The color of the bars
nrichment. The complete list of identified GOBPs is displayed in Supplemental
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1930committee approved the study, and participants gave
informed consent.
STATISTICAL ANALYSIS. Results are expressed as
mean  SE or median (interquartile ranges).
Normality of data was analyzed by the Kolmogorov-
Smirnov test. For multiple comparisons, we used
analysis of variance followed by Tukey post hoc test
or Kruskal-Wallis test followed by Dunn analysis. C5
in participants with incipient versus generalized
atherosclerosis was analyzed by Mann-Whitney U
test. The association between C5 and generalized
atherosclerosis, adjusting for the identified con-
founders, was assessed by multivariate logistic
regression analysis. The association between C5 and
plaque burden or calcification adjusting for the
identified confounders was assessed by multivariate
linear regression analysis. Statistical analysis were
performed using SPSS software version 23.0 (SPSS,
Inc., Chicago, Illinois). Statistical significance was
assigned at p < 0.05.
RESULTS
QUANTITATIVE PROTEOMICS REVEALS INCREASED
ABUNDANCE OF LIPID TRANSPORT, HEMOSTASIS,
AND COMPLEMENT PROTEINS IN THE MEDIA AND
INTIMA LAYERS OF EARLY ATHEROSCLEROSIS
PLAQUES. We analyzed separately the intima and
media layers of aortas with FS and FL plaques as well
as the media of healthy aortas (Supplemental
Figure 2). More than 6,500 proteins were identified
in the media and in the intima of atherosclerotic
plaques. After discarding proteins identified with a
single peptide, proteins present in <60% of either
media or intima samples, and protein isoforms, 3,079
medial and 3,332 intimal proteins remained (hence-
forth, “identified proteins”) (Supplemental Table 1).
Of those, 2,660 proteins were common to media and
intima layers, with total abundance similar in the
different compartments and tissues (Supplemental
Figure 3). However, the media layer had higher
amounts of proteins belonging to the vascular sys-
tem, whereas the intima layer had higher amounts of
proteins known to be present in liver and plasma
(Supplemental Figure 3).
In total, 340 proteins in FS media (184 up and 156
down) and 328 in FL media (149 up and 179 down)
significantly changed their relative abundance when
compared with healthy media (Figure 1A). The
changes in FS and FL media were quite similar,
showing a high correlation (Figure 1B). The up-
regulated proteins were significantly enriched in
biological categories mostly related to hemostasis/
coagulation, lipid transport/metabolism, andcomplement system. The relatively few down-
regulated processes were mostly related to protein
synthesis and regulation (rRNA processing and
translation) (Figure 1C). In the intima layer, 557 pro-
teins were significantly altered in FL (229 up and 328
down) when compared with FS plaques (Figure 2A).
The biological processes increased in FL intima were
quite similar to those found in the media, but pro-
teins related to the immune response (including
immunoglobulin superfamily) were also increased in
the intima. Down-regulated processes were even less
common in the intima than in the media (Figure 2B).
PROTEINS FROM THE COMPLEMENT ACTIVATION
PATHWAY GRADUALLY ACCUMULATE WITH
DISEASE PROGRESSION IN EARLY ATHEROMA. We
further inspected the biological process altered by
analyzing abundance changes in functional sub-
categories produced by coordinated protein alter-
ations (Systems Biology Triangle model) (12) as well
as the individual behavior of their components. In-
spection of the proteins related to lipid transport
revealed a generalized increase in apolipoproteins
and associated proteins, and in proteins related to
lipid transfer and receptors, in both the media and
intima (Supplemental Figures 4A, 5A, and 5B). These
proteins gradually accumulated in the plaques,
reaching up to 6% of the total protein amount in FL
intima (Supplemental Figure 5C), due mainly to apo-
lipoproteins (Supplemental Figure 5D). A generalized
increase of proteins was also observed in the group of
hemostasis/coagulation (Supplemental Figures 4B,
6A, and 6B). Absolute accumulation of these pro-
teins in the plaques occurred mainly in the intima,
mostly due to the common coagulation pathway and
hemostasis regulators (Supplemental Figures 6C and
6D). Among proteins involved in the immune
response, antigen and Ig receptors showed a gener-
alized relative abundance increase in the intima
(Supplemental Figures 4C, 7A, and 7B). These pro-
teins strongly accumulated in the intima, reaching up
to 4% of total protein composition (Supplemental
Figures 7C and 7D).
Inspection of proteins of the complement system
revealed a generalized increase in relative abundance
of proteins involved in complement activation in both
media and intima (Figures 3A and 3B, Supplemental
Figure 4D). Regulators showing increased expres-
sion were mostly of the alternative pathway, while
CD59 (a membrane attack complex [MAC] inhibitor)
was decreased (Figure 3B). The total absolute abun-
dance of complement proteins increased in parallel
with disease progression, reaching up to 2.5% of total
composition (Figure 3C). The absolute increase in the
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(A) Heat map of the Zq values representing identified proteins that increase (red) or decrease (blue) in the intima layer of fibrolipidic (FLi) versus fatty
streak (FSi) plaques. The inset at the right shows the statistically significant abundance changes in samples of FLi versus FSi. (B) Enrichment analysis of
significant altered proteins identified in the intimal layer of atherosclerotic tissue. The bars show the relative proportion of changing proteins that belong to
each one of the main biological processes (GOBP categories) that are significantly enriched. Bars are color coded according to log2(p), where p refers to
the p value obtained for Bonferroni enrichment. Only the significantly enriched GOBPs are shown [log2(p) ¼ 5 correspond to a p value <0.05]. The
complete list of identified GOBPs are listed in Supplemental Table 3.
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FIGURE 3 Changes in the Proteins Related to the Complement System in Early Atherosclerotic Tissue
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1933media was mainly due to proteins from the comple-
ment activation, while in the intima both classical
and complement activation proteins accumulated
(Figure 3D).
Protein-protein association network analysis
revealed strong interactions with high confidence
associations between proteins belonging to the 4
different functional groups (Supplemental Figure 8).
Finally, we observed a strong positive correlation of
the abundance of the complement system with the
other 3 functional groups in the intima, and also with
the lipid transport/metabolism group in the media
(Figure 4).
To further study the prominent changes in com-
plement activation observed in FS and FL plaques, we
selected C5 as a representative MAC molecule. The
gradual increase in C5 protein levels in the media and
intima with increasing plaque complexity was
confirmed by Western blot (Figure 5A). FS and FL
plaques also showed increased C5-positive staining,
colocalizing with a marker of complement activation
(C5b-9 or MAC) (Figure 5B). Increased complement
activation in media and intima of FL plaques was also
confirmed by measuring the abundance of C5a and
C5b-9 complex in early atherosclerotic tissue-
conditioned medium by ELISA (Figure 5C). More-
over, C5 showed a strong positive correlation with
C5a and C5b-9 protein levels in tissue-conditioned
medium (Figure 5C), while, consistently, the MAC
inhibitor CD59 showed a negative correlation
(Supplemental Figure 9). Finally, no significant dif-
ferences in mRNA levels of C5, complement decay-
accelerating factor or CD59 were observed between
H, FS, and FL aortic samples (SupplementalFIGURE 3 Continued
(A) Analysis of coordinated protein changes for the different complemen
using the FDR. (B) Quantitative data for all identified proteins related to
bars indicate Zq values expressed as mean  SD from 6 to 12 independe
variance followed by Tukey’s post hoc test (media layer) or Student’s t-te
Methods (*false discovery rate < 0.05). (C) Summed absolute abundanc
Values are mean  SD from 6 to 12 independent samples per group (*p#
using analysis of variance test followed by Tukey post hoc test. (D) Distr
Box plots represent the median and 25 and 75 percentiles, and error ba
C1QB ¼ complement C1q subcomponent subunit B; C1QBP ¼ compleme
subcomponent subunit C; C1R ¼ complement C1r subcomponent; C1S ¼
C4A ¼ complement C4-A; C4B ¼ complement C4-B; C5 ¼ complement
component C8 alpha chain; C8B ¼ complement component C8 beta cha
CD55 ¼ complement decay-accelerating factor; CD59 ¼ CD59 glycoprote
CFHR1 ¼ complement factor H–related protein 1; CFHR2 ¼ complement
CFHR4 ¼ complement factor H–related protein 4; CFHR5 ¼ complemen
intima; FLm ¼ fibrolipidic media; FSi ¼ fatty streak intima; FSm¼ fatty
MASP2 ¼ mannan-binding lectin serine protease 2; other abbreviationsFigure 10), indicating that complement accumula-
tion was not due to increased protein synthesis.
COMPLEMENT C5 IN PLASMA IS AN INDEPENDENT
PREDICTOR OF GENERALIZED SUBCLINICAL
ATHEROSCLEROSIS IN 2 DIFFERENT POPULATIONS. To
study whether complement activation in early
atherosclerosis lesions was reflected in plasma, we
measured C5 plasma levels in 360 male participants
in the PESA study. Overall, they were young to
middle-aged low-risk individuals, categorized by
2DVUS imaging into 2 groups having incipient (0 to
2 plaques) or generalized (>2 plaques) subclinical
atherosclerosis (Table 1). We found that C5 plasma
levels were higher in the individuals with general-
ized subclinical disease than in those with incipient
atherosclerosis (Table 1). Logistic regression analysis
identified C5 as independent predictor of the pres-
ence of generalized atherosclerosis in addition to
other CV risk factors (Table 2). Furthermore, multi-
variate linear regression analysis showed indepen-
dent associations between volumetric plaque
burden, measured by 3DVUS (16), and C5 levels
(Table 3). Finally, coronary artery calcification,
measured by CT, was also independently associated
with C5 levels (Table 3).
Because our PESA subcohort included only men,
we further analyzed C5 plasma levels in 394
asymptomatic patients included in the NEFRONA
study as a control group (15) (Table 1). C5 levels were
also higher in individuals with generalized subclini-
cal atherosclerosis than in those with incipient
atherosclerosis in this population (Table 1). Further-
more, multivariable logistic regression analysis
identified C5 as an independent predictor of thet system subcategories calculated using the SBT model; statistical significance was expressed
the complement system and subcategorized according to their specific characteristics. The
nt samples per group. Statistically significant changes were calculated using either analysis of
st (intima layer) (filled bars: p < 0.05) or the WSPP model, as explained in the Supplemental
e of the proteins involved in the different subcategories related to the complement system.
0.05 FLi vs. H; †p # 0.05 FLi vs. FSm; ‡p# 0.05 FLi vs. FLm; #p # 0.05 FLi vs. FSi) calculated
ibution of absolute abundances of proteins from the complement system in each subcategory.
rs 10 and 90 percentiles. C1QA ¼ complement C1q subcomponent subunit A;
nt component 1 Q subcomponent-binding protein, mitochondrial; C1QC ¼ complement C1q
complement C1s subcomponent; C2 ¼ complement C2; C3 ¼ complement C3;
C5; C6 ¼ complement component C6; C7 ¼ complement component C7; C8A ¼ complement
in; C8G ¼ complement component C8 gamma chain; C9 ¼ complement component C9;
in; CFB ¼ complement factor B; CFD ¼ complement factor D; CFH ¼ complement factor H;
factor H–related protein 2; CFHR3 ¼ complement factor H–related protein 3;
t factor H–related protein 5; CFI ¼ complement factor I; FCN2 ¼ ficolin-2; FLi ¼ fibrolipidic
streak media; H ¼ healthy; MASP1 ¼ mannan-binding lectin serine protease 1;
as in Figure 2.






























































H FSm FLm FSi FLi
Pearson correlation analysis of the abundance of complement system with (A) Ig superfamily, (B) lipid transport, and (C) hemostasis
coagulation in both the media and the intima layers. Abbreviations as in Figures 2 and 3.
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1934presence of generalized atherosclerosis in addition
to other CV risk factors in the NEFRONA population
(Table 2). In contrast, C5a levels were not different
between individuals with generalized subclinical
disease than in those with incipient atherosclerosis
either in PESA (3.89 ng/ml [2.10 to 7.81 ng/ml] vs.
4.18 ng/ml [2.34 to 9.23 ng/ml]; p ¼ NS) or NEFRONA
(4.52 ng/ml [2.43 to 8.21 ng/ml] vs. 3.81 ng/ml [2.41
to 6.47 ng/ml]; p ¼ NS) studies.DISCUSSION
TOPOLOGICALLY RESOLVED ANALYSIS OF THE
PLAQUE PROTEOME. In the present study, we have
performed a deep quantitative proteomics analysis of
the intimal and medial layers of early human
atherosclerotic plaques. We found that although a
considerable number of the identified proteins are
shared between media and intima, their actual
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H FSm FLm FSi FLi
(A) Validation of complement C5 in the tissue samples used for the proteomic study by Western blot. Relative band intensity values are mean  SD of
between 6 and 12 independent samples per group; results are normalized to GADPH. (B) Immunohistochemistry of complement C5 in fatty streak (FS) and
fibrolipid (FL) lesions in subclinical atherosclerotic tissues showing colocalization with MAC (B7C9 staining). (C) Enzyme-linked immunosorbent assay
analysis of soluble levels of complement C5, C5b-9 and C5a in tissue-conditioned medium; the charts show Pearson correlation between the soluble
levels of complement C5, C5b-9 and C5a. *p# 0.05 vs. H, †p # 0.05 vs. FSm, ‡p # 0.05 vs. FLm, #p # 0.05 vs. FSi, calculated using analysis of variance
test followed by Tukey post hoc test. Box plots represent the median and 25th and 75th percentiles, and error bars 10 and 90 percentiles. Abbreviations
as in Figures 2 and 3.
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(n ¼ 91) p Value
Age, yrs 49 (46–52) 48 (46–51) 50 (47–52) <0.001 55 (46–63) 53 (43–60) 61 (57–67) <0.001
Male 100.0 100.0 100.0 NS 53.5 47.2 74.7 <0.001
Smoking 26.9 17.7 36.8 <0.001 60.6 57.1 72.5 <0.05
Diabetes 2.5 0.5 4.6 <0.01 11.2 8.2 20.9 <0.001
SBP, mm Hg 120  12.01 119  11.9 123  12 <0.01 132  17 130  17 141  16 <0.001
DBP, mm Hg 76  9 74  9 77  9 <0.01 80  10 79  10 83  9 <0.005
Total cholesterol, mg/dl 203 (182–226) 199 (177–220) 205 (188–234) <0.01 203  34 201  34 208  35 NS
HDL cholesterol, mg/dl 43  10 44  10 42  10 NS 51 (42–62) 51 (42–64) 50 (43–60) NS
LDL cholesterol, mg/dl 140  31 141  29 139  33 NS 127  32 126  32 130  31 NS
Triglycerides, mg/dl 95 (74–132) 91 (68–126) 105 (77–144) <0.001 99 (71–140) 92 (67–133) 115 (83–150) <0.001
Glucose, mg/dl 92 (87–99) 92 (87–97) 92 (87–101) NS 97 (89–106) 96 (88–104) 105 (95–117) <0.001
hsCRP, mg/l 0.12 (0.06–0.21) 0.11 (0.06–0.19) 0.12 (0.06–0.22) NS 1.5 (0.8–3.0) 1.4 (0.8–2.9) 1.9 (0.9–3.7) NS
C5, ug/ml 53.7 (17.7–137.4) 50.8 (17.7–137.4) 58.0 (19.9–119.6) <0.001 50.4 (0.6–227.4) 49.3 (0.6–184.9) 57.9 (11.6–227.4) 0.005
Values are median (interquartile range), %, or mean  SE.
DBP ¼ diastolic blood pressure; HDL ¼ high-density lipoprotein; LDL¼ low-density lipoprotein; NS ¼ nonsignificant; PESA ¼ Progression of Early Subclinical Atherosclerosis; SBP ¼ systolic blood pressure.
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1936proportions are quite different in each compartment.
Besides, a large proportion of these proteins are
known to be synthesized in extravascular tissues
(e.g., albumin or apolipoproteins in the liver), sug-
gesting that an important amount of the proteins
identified in atherosclerotic plaques could be derived
either from direct interaction (e.g., with receptors) or
by a passive retention from the blood. The percola-
tion of soluble mediators from the blood to the intima
and media layers could be favored by radial mass
transport, conveyed by advective hydraulic conduc-
tance (17). In fact, a previous study showed a corre-
lation between the abundance of 4 major plasma
proteins in the intima (albumin, apolipoprotein B,
immunoglobulin [Ig] G, and fibrinogen) and the
presence and growth of early coronary atherosclerosis
(18). Another interesting result is that the molecular
changes that take place during atherogenesis in the
media of FL plaques are already present in the media
layer of FS plaques. In asymptomatic patients with
atherosclerotic plaques of the PESA study, 18F-FDG
uptake was mainly detected in plaque-free arterial
segments, suggesting that a high metabolic activity
could be associated with the medial layer in early
atherosclerosis (19). On the whole, our data highlight
the contribution of both the media and intima layers
during the different stages of atherogenesis.
Our proteomics study has identified more than
6,000 proteins from which more than 2,500 well-
validated proteins were found in both the media
and intima layers. These proteins were enriched in 4main categories. One of the categories related to lipid
advective radial transport and metabolism, which fits
with the view that initial vessel wall injury derives
from plasma lipid transport and intimal retention
within the arterial wall (4). However, our
compartment-resolved proteomic studies indicated a
previously unappreciated contribution of the media
layer to lipid and lipoprotein deposition and meta-
bolism within the arterial wall. Another main cate-
gory was hemostasis, a tightly regulated process
involving platelet activation, blood clotting, and
vascular repair. A previous study detected signifi-
cantly higher activities of tissue factor, FII, FX, and
FXII in early atherosclerotic lesions than in stable
advanced atherosclerotic lesions (20), suggesting an
enhanced procoagulant state in early atherosclerosis.
In agreement, we have shown an increase of proteins
of different coagulation pathways (e.g., FX, thrombin,
and fibrinogen) and inhibitors (e.g., SERPINs) both in
the media and intima layers. Finally, we also showed
increased presence of Igs in atherosclerotic plaques,
which has been previously documented (21). Ig re-
ceptors could favor the accumulation of Igs; among
them, increased significant levels of Igll5 and PIGR
are observed in the intima of early atherosclerotic
plaques for the first time, whose role deserves further
studies.
THE ROLE OF COMPLEMENT ACTIVATION IN EARLY
ATHEROSCLEROSIS. Our data highlighted an in-
crease of proteins related to complement activation
mainly associated with the classical (or so called “Ig-
TABLE 2 Logistic Regression Analysis of the Association With the Presence
of Subclinical Generalized Atherosclerosis
Beta p Value OR (95% CI)
Univariate analysis
PESA
C5 0.347 0.001 1.41 (1.16–1.72)
Age 0.255 0.008 1.29 (1.07–1.56)
Smoking 0.49 <0.0001 1.63 (1.38–1.94)
SBP 0.335 0.001 1.40 (1.14–1.70)
DBP 0.276 0.005 1.32 (1.09–1.60)
Diabetes 0.33 0.014 1.39 (1.07–1.81)
Total cholesterol 0.238 0.015 1.27 (1.05–1.54)
Triglycerides 0.273 0.008 1.31 (1.07–1.61)
LDL cholesterol 0.101 0.29 0.90 (0.75–1.09)
Glucose 0.158 0.111 1.17 (0.96–1.42)
NEFRONA
C5 0.38 0.001 1.46 (1.17–1.82)
Age 1.044 <0.0001 2.84 (2.05–3.93)
Sex 0.597 <0.0001 1.82 (1.40–2.36)
Smoking 0.335 0.009 1.40 (1.09–1.80)
SBP 0.649 <0.0001 1.91 (1.49–2.45)
DBP 0.355 0.003 1.43 (1.12–1.81)
Diabetes 0.339 0.001 1.40 (1.14–1.72)
Total cholesterol 0.191 0.113 1.21 (0.96–1.53)
Triglycerides 0.272 0.018 1.31 (1.05–1.65)
LDL cholesterol 0.113 0.378 1.20 (0.87–1.44)
Glucose 0.422 0.0003 1.52 (1.22–1.91)
Multivariate analysis
PESA
C5 0.263 0.016 1.30 (1.05–1.61)
Age 0.211 0.046 1.23 (1.00–1.52)
Smoking 0.573 <0.0001 1.77 (1.43–2.19)
SBP 0.421 0.02 1.52 (1.07–2.17)
DBP 0.037 0.835 0.96 (0.68–1.36)
Diabetes 0.351 0.024 1.42 (1.05–1.93)
Total cholesterol 0.34 0.004 1.40 (1.12–1.79)
Triglycerides 0.116 0.312 1.123 (0.90–1.41)
LDL cholesterol 0.135 0.221 0.87 (0.70–1.08)
Glucose 0.082 0.533 0.92 (0.71–1.19)
NEFRONA
C5 0.408 0.005 1.50 (1.13–2.00)
Age 1.01 0.016 2.74 (1.74–4.32)
Sex 0.433 0.016 1.54 (1.08–2.19)
Smoking 0.342 0.053 1.41 (0.99–1.99)
SBP 0.296 0.178 1.34 (0.87–2.07)
DBP 0.036 0.868 0.96 (0.63–1.47)
Diabetes 0.105 0.536 1.11 (0.80–1.55)
Total cholesterol 0.017 0.97 0.98 (0.40–2.39)
Triglycerides 0.025 0.905 1.02 (0.68–1.59)
LDL cholesterol 0.253 0.57 1.29 (0.54–3.08)
Glucose 0.309 0.12 1.36 (0.92–2.01)
Values in bold indicate statistical significance. To calculate odds ratios continuous variables are
expressed in units of SD. In PESA, SD values are: C5: 19.31 mg/ml; age: 3.73 years; SBP:
12.09 mm Hg; DBP: 9.42 mm Hg; total cholesterol: 35.01 mg/dl; triglycerides: 59.81 mg/dl; LDL
cholesterol: 31.05 mg/dl; glucose: 12.44 mg/dl. In NEFRONA, C5: 34.24 mg/ml; age: 11.82 years;
SBP: 16.95 mm Hg; DBP: 9.77 mm Hg; total cholesterol: 34.20 mg/dl; triglycerides: 68.85 mg/dl;
LDL cholesterol: 32.15 mg/dl; glucose: 23.63 mg/dl.
CI ¼ confidence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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1937dependent”) pathway. In addition to Igs, a variety of
potential triggers has been described in the athero-
sclerotic lesion that could activate the complement
system, such as modified LDLs (22), cholesterol crys-
tals (23), and hemostatic proteins (24). Thus, we
observed a positive correlation between lipid meta-
bolism/transport and complement both in the intima
and media layers, and also with Ig and hemostasis
groups in the intima layer, supporting the functional
relationship between the main categories detected in
our study. Atherosclerotic plaques thus seem to be a
privileged surface for complement activation with
several triggers potentially involved in complement
deposition and activation.
The complement activation observed by prote-
omics was validated by Western blot and immuno-
histochemistry studies confirming the increase in C5
protein levels in atherosclerotic plaques. Moreover,
C5 colocalized with C5b-9/MAC in tissue and C5 levels
showed a positive correlation with C5a and C5b-9 in
tissue-conditioned medium, confirming tissular
complement activation. Interestingly, this was
accompanied with a decrease on the MAC regulator
CD59 in FL tissue and tissue-conditioned media. The
functional consequences of complement activation
may be related to the proliferation of smooth muscle
and endothelial cells, accompanied by the release of
various chemotactic, proadhesion, and procoagulant
cytokines from these cells (25). Atherosclerosis can be
decreased by increasing CD59 (CD59 transgenic mice)
and administering either antiC5 antibody (26) or siR-
NAC5 in the liver (confirmed by reduced C5 plasma
levels) (27) in ApoE KO mice. However, the results of
previous interventional studies mainly targeting C5
in CV patients were unconvincing (28). Several ex-
planations could account for the lack of effect of these
C5 therapies (e.g., pexelizumab), such as the delay on
the initiation of therapy or the sustained MAC acti-
vation in plasma of CV patients contrasting with the
complete MAC inhibition observed in cell culture
studies (29). On the whole, strategies to halt com-
plement activation could be of therapeutic value,
although their implementation in the clinical setting
deserves further studies.
COMPLEMENT C5 AS A BIOMARKER OF SUBCLINICAL
ATHEROSCLEROSIS. The increased protein levels of
C5 observed in atherosclerotic plaques was not
accompanied by increased mRNA levels; this, along
with the high levels of extravascular proteins in early
atherosclerotic plaques, led us to hypothesize a
plasmatic origin of C5. Then, we tested the levels of
C5 in plasma of subjects with subclinical atheroscle-
rosis. In our PESA subcohort, plasma C5 was higher in
TABLE 3 Linear Regression Analysis of the Association With Plaque Burden
and CAC Score in the PESA study
Plaque Burden CAC Score
Beta p Value Beta p Value
Univariate analysis
C5 0.154 0.001 0.176 0.0002
Age 0.155 0.001 0.13 0.006
Smoking 0.28 <0.0001 0.113 0.017
SBP 0.088 0.065 0.13 0.006
DBP 0.095 0.046 0.147 0.002
Diabetes 0.165 <0.001 0.124 0.009
TotalCholesterol 0.048 0.313 0.02 0.679
Triglycerides 0.153 0.001 0.084 0.075
LDLCholesterol 0.254 0.528 0.469 0.956
HDLCholesterol L0.097 0.041 0.000457 0.992
Glucose 0.067 0.161 0.088 0.063
Multivariate analysis
C5 0.101 0.02 0.144 0.002
Age 0.229 <0.0001 0.092 0.052
Smoking 0.29 <0.0001 0.094 0.047
SBP 0.144 0.044 0.033 0.674
DBP 0.037 0.605 0.109 0.162
Diabetes 0.149 0.005 0.1 0.078
Total cholesterol 0.139 0.005 0.003 0.95
Triglycerides 0.036 0.444 0.051 0.321
LDL cholesterol 0.029 0.526 0.008 0.865
HDL cholesterol 0.021 0.658 0.045 0.376
Glucose 0.048 0.361 0.006 0.916
Values in bold indicate statistical significance.
CAC ¼ coronary artery calcification; other abbreviations as in Table 1.
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1938asymptomatic individuals with generalized athero-
sclerosis (>2 plaques) than in those with
incipient atherosclerosis, independently of risk fac-
tors. This finding was validated in NEFRONA study
participants free from clinical CV disease (Central
Illustration). In contrast, C5a was similar between
subjects with generalized versus incipient athero-
sclerosis in both cohorts, in agreement with a previ-
ous study where C5a was not associated to surrogate
markers of subclinical atherosclerosis such as
IMT (30).
Both the PESA and NEFRONA studies analyzed the
presence of atherosclerotic plaques in different ter-
ritories (carotid and femoral arteries) by 2DVUS.
However, the PESA study includes 3DVUS analysis of
volumetric plaque burden and CT assessment of cor-
onary calcification. In the PESA study, inclusion of
plaque burden quantification in the detection of pla-
que presence provided a closer match association
with global CV risk (16). Moreover, the CACS is anexcellent surrogate marker of underlying coronary
atherosclerosis burden and is probably the most
useful current way to improve risk assessment among
individuals at intermediate risk (31). Interestingly,
both plaque burden and CACS are associated with CV
events (2). Our study shows a significant positive as-
sociation of C5 with atherosclerosis burden and
calcification in asymptomatic PESA study partici-
pants, independently of risk factors. However, in
such a complex disease such as atherosclerosis, a
single biomarker may be insufficient to detect
atherosclerotic plaques and/or to predict CV risk.
Thus, the potential role of C5 as subclinical athero-
sclerosis biomarker should be assessed together with
other biomarkers of different pathological mecha-
nisms as those observed in our proteomic study of
plaques.
STUDY LIMITATIONS. We have studied aortic tissues
due to easier accessibility of samples, but the analysis
of coronary vessels would be more relevant for
myocardial infarction. However, we cannot macro-
scopically separate intima and media of coronary ar-
teries, which would preclude the topological analysis
performed in the present study. In the PESA study,
we did not have information on plaque characteriza-
tion to define plaque types in a similar way as we did
in the in vitro study; moreover, FS lesions are not
detected by common noninvasive imaging methods
following standard definitions; thus, we used the
extent of atherosclerosis disease measured as the
number of plaques present in each participant
(incipient [0 to 2 plaques] vs. generalized [>2 pla-
ques]) to define progressive stages of atherosclerosis.
Ultimately, the clinical validation of the plasma C5 as
an early biomarker of CV disease will come from the
association with future incident CV events. None-
theless, the validity of C5 is indirectly supported by
the consistent association with other validated
markers of disease severity and CV risk (larger plaque
volumes and mainly higher CACS). Future follow-up
data from the PESA or other prospective cohorts will
help confirm this hypothesis by evaluating associa-
tions with CV outcomes.
CONCLUSIONS
Proteomic analysis of aortic tissues highlights com-
plement accumulation and activation in the intima of
early atherosclerotic plaques. This was paralleled by
elevated complement C5 levels in plasma of low-risk
asymptomatic individuals, correlating with plaque
volume and CACS, 2 markers of disease severity and
CENTRAL ILLUSTRATION Plaque Proteomics Identifies Complement C5 as a Biomarker of
Subclinical Atherosclerosis
Martínez-López, D. et al. J Am Coll Cardiol. 2020;75(16):1926–41.
(Top) Schematic of proteomic analysis of media and intima of fatty streaks (FS) and fibrolipidic (FL) plaques. (Bottom) Odds ratio (expressed in units of SD) of the
association of complement C5 and risk factors with generalized atherosclerosis (>2 plaques), adjusted for potential confounding factors.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Complement C5 protein accumulates in the intima
layer of early atheromatous lesions, and plasma levels
of complement C5 are elevated in asymptomatic in-
dividuals in proportion to the extent of
atherosclerosis.
TRANSLATIONAL OUTLOOK: Clinical and epide-
miological studies are needed to validate the accuracy
and reliability of plasma complement C5 protein levels
as a biomarker of the extent of atherosclerosis in
various populations and its utility as a screening
method.
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1940CV events. Thus, the identification of C5 as a
biomarker of atherosclerotic burden in subclinical
atherosclerosis provides an additional potential tool
for CV risk prediction.
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